Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03373903 · ClinicalTrials.gov registry record · Phase 2

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

A Phase 2 study of Respiratory Tract Infections, sponsored by Restorbio.

Active
Registry status
Phase 2
Development phase
652
Enrollment target
1
Study location

NCT03373903 is a Phase 2 study of Respiratory Tract Infections that is active but no longer recruiting, run by Restorbio. The registered enrollment target is 652 participants, below the 2,731-participant average among 15 other Respiratory Tract Infections trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03373903, a Phase 2 study of Respiratory Tract Infections, is active but no longer recruiting, sponsored by Restorbio.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
652 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.

Interventions

  • OTHER Placebo
  • DRUG BEZ235
  • DRUG BEZ235 plus everolimus (RAD001)

Study Locations (1)

Kansas

  • Heartland Research Associates - Wichita

Trial Details

FieldValue
Enrollment Target 652 participants
Start Date 2017-11-15
Est. Completion 2018-07
Phase Phase 2

Sponsor

Restorbio

3 total trials

What the Registry Record Tells You About NCT03373903

The ClinicalTrials.gov registry entry for NCT03373903 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 652 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,731-participant average among 15 other Respiratory Tract Infections trials with a reported enrollment target (76% lower). The listed sponsor is Restorbio, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Tract Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03373903 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT03373903 about?

NCT03373903 is a clinical study titled "Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly". The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.

What is the current status of trial NCT03373903?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 652 participants. The study started on 2017-11-15. Estimated completion is 2018-07.

What conditions does trial NCT03373903 study?

This clinical trial studies the following conditions: Respiratory Tract Infections.

What interventions are being tested in trial NCT03373903?

The interventions under investigation include: Placebo (OTHER), BEZ235 (DRUG), BEZ235 plus everolimus (RAD001) (DRUG).

Who is sponsoring clinical trial NCT03373903?

This trial is sponsored by Restorbio, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03373903 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Respiratory Tract Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.